Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Baricitinib treatment can help regrow scalp hair and eyebrows or eyelashes in people with severe alopecia areata.

Aumolertinib is effective and well-tolerated for treating advanced lung cancer with EGFR mutations.

Ritlecitinib is a new treatment for severe hair loss in people 12 and older.

Topical tofacitinib shows promise as a future treatment for alopecia areata.

Sonidegib and vismodegib have different side effects and reporting patterns.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

Tofacitinib may slow hair loss in scarring alopecias but is unlikely to regrow significant hair.

Baricitinib successfully treated severe hair loss.

JAK inhibitors like tofacitinib may effectively treat alopecia in children without major side effects.

New cancer treatments show promise in reducing tumor growth and improving skin regeneration in mice.

Abrocitinib may effectively treat stubborn alopecia universalis.

Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.

Upadacitinib effectively treats psoriasis and lichen planus together.

A medicine called tofacitinib worked to treat a hair loss condition linked with a muscle and skin disease.

Baricitinib significantly regrows hair in nasal, genital, and beard areas for severe alopecia areata.

Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.

Topical tofacitinib may help regrow hair in children with alopecia totalis.

Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.

Baricitinib and its combination with lonafarnib improve fat cell formation in certain genetic disorders.

Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.

JAK inhibitors show promise for treating alopecia areata but have serious side effects.

CS12192 effectively treats alopecia areata with better safety than current options.

Blocking JAK-STAT signaling can lead to hair growth.

Baricitinib is effective as a treatment for severe hair loss.

JAK inhibitors are effective and generally safe for treating alopecia areata, but monitoring for side effects is important.

Baricitinib can help improve hair loss and skin color issues in people with Down syndrome.

Selumetinib causes fewer and less severe skin issues in children than binimetinib.

Oclacitinib effectively treated a skin condition in dogs that didn't respond to other immunosuppressants.

Ritlecitinib provides new treatment options for diverse alopecia areata patients.